Document is current
Any future updates will be listed below
-
Authors
Shao, Yu-Yun https://orcid.org/0000-0001-7334-1912
Chen, Ching-Tso
Chuang, Chien-Huai
Su, Tung-Hung
Ho, Ming-Chih
Tseng, Tai-Chung
Liu, Tsung-Hao
Wu, Tsung-Che
Cheng, Ann-Lii https://orcid.org/0000-0002-9152-6512
Hsu, Chih-Hung
-
Funding
Funding for this research was provided by:
AstraZeneca
Ministry of Health and Welfare (MOHW112-TDU-B-211-144002)
National Taiwan University Hospital (NTUH. 108-S4150)
- License Information
-
More Information
Article History
Received: 11 November 2024
Revised: 10 February 2025
Accepted: 10 March 2025
First Online: 24 March 2025
Competing interests
: YYS had received honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Ipsen, Merck, Ono, and Roche. THS received research grant from Gilead Sciences, served as a consultant for Gilead Sciences, and was on speaker’s bureaus for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, Roche and Sysmex. TCT has served on speaker’s bureaus for Fujirebio, Bristol-Myers Squibb, and Gilead Sciences and received grant support from Gilead Sciences. TCW has received honoraria from Astra Zeneca, Bayer, and Roche. CHH has served as a consultant in advisory boards of Roche and AstraZeneca, has received honoraria from Bristol Myers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, and Roche, and has received research grant from AstraZeneca, Bayer, Eli Lilly, Genentech, and Roche.
: This study was approved by the Research Ethical Committee of National Taiwan University Hospital (protocol No. 201910075MIPD) and Ministry of Health and Welfare, Taiwan and performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants.
